ULD & PERISHABLES SUPPLEMENT~ Challenges of the pharma cold chain

As any manufacturer, producer or logistics expert will tell you, the global supply chain for temperature sensitive commodities is becoming increasingly complex.


For the pharmaceutical and biotech sector, the increasing value of individual products in terms of development and replacement cost, as well as their intrinsic value, is also placing a further element of potential ‘risk’ that all participants within the supply chain must adequately deal with. In addition, the continuing threat posed by counterfeiting is causing manufacturers to constantly review the distribution-to-market processof their products.

There are of course many ‘guidelines’ and ‘recommendations’ for the safe transportation of temperature sensitive commodities, but what is becoming increasingly clear is that consumer safety (particularly as seen by the WHO, FDA,& EU) is placing clear responsibility on producers and manufacturers for effective management of their cold chain.

Manufacturing growth & globalisation
A recent assessment of the global pharmaceutical market by Ernst & Young forecast that it will grow to US$897 billion by 2011, equivalent to a cumulative annual growth rate of 6.9 per cent. Furthermore, strong growth in the 10 European markets commodities, but what is becoming increasingly clear is that consumer safety (particularly as seen by the WHO, FDA,& EU) is placing clear responsibility on producers and manufacturers for effective management of their cold chain.

Manufacturing growth & globalisation
A recent assessment of the global pharmaceutical market by Ernst & Young forecast that it will grow to US$897 billion by 2011, equivalent to a cumulative annual growth rate of 6.9 per cent. Furthermore, strong growth in the 10 European markets that joined the European Union in 2004 will help boost European sales over the next fi ve years.